Dr. Jack West reviews the pros and cons of using osimertinib first line vs. “saving” it as a second line therapy, trying to determine the optimal sequence for EGFR-directed therapy in advanced EGFR mutation-positive NSCLC.
Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017)
